AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifetime Total Physical Activity Questionnaire
Description: * Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite (EPIC)
Description: * Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expanded Prostate Cancer Index Composite (EPIC)
Description: * Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: International Physical Activity Prevalence Study Environmental Module
Description: -The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
Study NCT00664170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2
Study NCT02224664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 5mg QD
Study NCT02224664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 15 mg QD
Study NCT02224664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Study NCT02224664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 25 mg QD
Study NCT04177836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness intervention
Description: Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
Study NCT04177836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
Study NCT03552783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FFL + Cognitive Behavioral Therapy
Description: Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
Study NCT03552783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fathers for a Lifetime (FFL) only
Description: The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community
Study NCT04792229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Viberation
Description: WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
Study NCT04792229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Viberation
Description: WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
Study NCT04544566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product A
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin
Study NCT04544566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product A
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin
Study NCT04544566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product B
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin
Study NCT04544566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product B
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin
Study NCT04544566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
Study NCT04544566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
Study NCT03332069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated electro-hyperthermia
Description: Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
Study NCT03332069 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Study NCT03332069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation
Study NCT03332069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT03332069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03332069 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: High Dose Rate
Study NCT03332069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: High Dose Rate
Study NCT02455115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating mean arterial pressure
Description: In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
Study NCT02455115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
Study NCT01379209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines
Study NCT02455115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium ethylenediaminetetraacetic acid
Description: Extraction of 51Cr-EDTA measured for FF and GFR
Study NCT01672892 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
Study NCT01672892 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
Study NCT00784407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: harmonic scalpel device utilized intraoperatively
Description: harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
Study NCT00835536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 mg tablets
Description: 1 x 200 mg, single-dose non-fasting
Study NCT00835536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPEGUS™ 200 mg Tablets
Description: 1 x 200 mg, single-dose non-fasting
Study NCT01794845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Description: Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
Study NCT01794845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
Study NCT01794845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Fractionated Radiation Therapy
Description: Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
Study NCT01359696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0425
Description: Oral escalating dose
Study NCT01359696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenous repeating dose
Study NCT01255085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea protein
Description: Served in a tomato soup
Study NCT01255085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea fiber
Description: Served in a tomato soup
Study NCT01255085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Tomato Soup
Description: Served in a tomato soup
Study NCT03733730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
Study NCT03733730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
Study NCT03733730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +2.5 D Multifocal IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
Study NCT03733730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Routine small incision cataract surgery with IOL implantation
Study NCT02311686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g ethanol
Description: Alcohol single oral dose
Study NCT02311686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g ethanol
Description: Alcohol single oral dose
Study NCT02311686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g ethanol
Description: Alcohol single oral dose
Study NCT02311686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 60 g ethanol
Description: Alcohol single oral dose
Study NCT02311686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 80 g ethanol
Description: Alcohol single oral dose
Study NCT03100344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)
Study NCT03100344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)
Study NCT01795872 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Several diagnostic procedures
Description: No drug will be assigned, diagnostic assessment within the study.
Study NCT04402151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Description: Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT).
Study NCT04402151 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will receive standard of care radiation therapy (SBRT)
Study NCT01686451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang
Description: Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
Study NCT01686451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Participants will receive 20mg of simvastatin daily for 4 weeks.
Study NCT00130377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell therapy
Description: autologous or allogeneic cells
Study NCT00130377 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cell therapy
Description: autologous or allogeneic cells
Study NCT02377778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
Study NCT02377778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
Study NCT03647254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education group
Description: Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
Study NCT01998295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/lumefantrine
Description: Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
Study NCT03423485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CG-100 Intraluminal Bypass Device
Description: Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
Study NCT02470247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Description: RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes.
Study NCT02470247 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM Remote Ischemic Preconditioning (SHAM RIPC)
Description: The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol).
Study NCT01850173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vertical vibration platform Fitybe
Description: They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 monotherapy dose escalation
Description: PF-07104091 will be administered orally
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + palbociclib + fulvestrant
Description: PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + palbociclib + letrozole
Description: PF-07104091 will be administered orally in combination with palbociclib and letrozole
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 monotherapy dose expansion (ovarian)
Description: PF-07104091 will be administered orally
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 monotherapy dose expansion (SCLC)
Description: PF-07104091 will be administered orally
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + Fulvestrant (post CDK4/6)
Description: PF-07104091 will be administered orally in combination with fulvestrant
Study NCT04553133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0704091 + Fulvestrant (post CDK4/6)
Description: PF-07104091 + fulvestrant (post 4/6) dose expansion
Study NCT06115291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell Test
Description: Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
Study NCT06115291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smell Test
Description: Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
Study NCT02008097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.
Study NCT01379209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT01379209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate
Study NCT01812525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 3%
Description: NaCl 3%: 4ml QID
Study NCT01812525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
Study NCT01812525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
Study NCT01379209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines
Study NCT04673994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Single, acute bout of high intensity interval exercise
Description: Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
Study NCT01565551 — intervention group
Intervention type: OTHER
Intervention: N/A (Observational Study)
Description: No Interventions: Observational Study
Study NCT04379180 — intervention group
Intervention type: DRUG
Intervention: Bosentan Tablets
Description: 2mg/kg, bid
Study NCT04379180 — intervention group
Intervention type: DRUG
Intervention: Sildenafil Tablet
Description: 1mg/kg, q6h/q8h
Study NCT04379180 — intervention group
Intervention type: DRUG
Intervention: Tadalafil Tablets
Description: 1mg/kg, qd
Study NCT02894138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alteplase
Study NCT02894138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01837303 — intervention group
Intervention type: PROCEDURE
Intervention: Pap smear
Description: A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo.
Study NCT02038842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: LIPO-5: 1mL IntraMuscular, 2 shots;
Study NCT02038842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HIV-B (MVATG17401)
Description: MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;